Gilead Sciences Inc · Moat analysis

Report previewGILD.USReport date Last updated
← Back to reports
Report contents
01

Industry landscape

Where the company competes: a four-firm HIV oligopoly, and two harder arenas

Gilead Sciences is best understood as an HIV company with two appendages. The company reported $28.7 billion of revenue in 2024, and HIV medicines supplied about $19.6 billion of it, roughly two-thirds (Gilead 2024 Form 10-K). The arena that decides Gilead's economics is therefore branded antiretroviral therapy for HIV-1, sold mainly in the US and Western Europe. That is a narrower definition than "biotech" and a different one from "oncology," and the difference matters: the HIV market has a structure that supports price, while the markets where Gilead is trying to build its next leg mostly do not.

The value chain runs from clinical trials to payer formularies

Gilead discovers and develops small-molecule antivirals and long-acting injectables, manufactures them at a mix of own sites and contract manufacturers, and sells through the three large US wholesalers, which ship to retail and specialty pharmacies. The real gatekeeper sits further downstream: pharmacy benefit managers and health plans decide formulary position, and patients rarely switch a regimen that has already driven their viral load to undetectable.

Geography shapes the economics more than the product does. The US accounted for roughly 70% of Gilead's product sales in 2024, and it is the only large market where a branded drug negotiates against rival brands instead of against an external reference price. Elsewhere, national health systems, voluntary licensing and access programs such as PEPFAR compress price and shift the mix toward volume. The practical consequence is that scale in this business is national, not global: a regimen that wins US formulary position captures most of its lifetime return inside one country.

Market structure: four sellers, one of them twice the size of its nearest rival

Concentration in HIV antivirals is high. Gilead, ViiV (majority-owned by GSK), Merck and Johnson & Johnson hold nearly all branded revenue; Gilead alone sells close to half. The shares below are estimates built from company-reported antiviral product sales, because no single authority publishes a global HIV share series.

CompanyAnchor regimensEst. share, 2024
GileadBiktarvy, Descovy, Genvoya, Sunlenca~50%
ViiV Healthcare (GSK)Dovato, Cabenuva, Juluca~20%
MerckDelstrigo, Pifeltro, Isentress~10%
Johnson & JohnsonEdurant, long-acting rilpivirine~5%
Generic and regional manufacturersVarious~15%

Apply the one-hand test: the meaningful branded sellers fit on four fingers. Barriers are correspondingly high, and they come from four places at once. A new HIV regimen needs a decade of clinical work and a combination that beats the incumbent's combination, not just a single better molecule. Approved products carry patent term plus five years of new-chemical-entity exclusivity in the US. Prescribers do not move a suppressed patient. And the long-acting injectable format that is now taking share requires nanosuspension manufacturing that few firms have qualified.

Hepatitis C and oncology sit in weaker structures

The contrast inside Gilead's own portfolio is instructive. Hepatitis C drugs cure the patient, so the addressable pool shrinks as treatment succeeds; segment revenue fell from a 2015 peak near $19 billion to roughly $1.7 billion in 2024, with AbbVie's Mavyret and low-cost generics in Egypt and India absorbing share. Oncology, built on the 2017 Kite acquisition, reached about $3.3 billion in 2024, of which Yescarta and Tecartus contributed close to $2 billion. Kite sells more cell therapy than any single rival, but the field includes Novartis, Bristol Myers Squibb, Johnson & Johnson, AstraZeneca and Roche, and every tumor type is a separate contest. Barriers there are high for different reasons, mainly manufacturing complexity and trial data, yet Gilead holds no dominant position in solid tumors, where Trodelvy competes against established antibody-drug conjugates.

The read-through for the moat is straightforward. Roughly two-thirds of revenue sits in a submarket where four sellers split the branded pool and the largest has held near half of it for years. That is the part of Gilead worth underwriting. HIV is also the part now being extended into prevention, with lenacapavir approved for pre-exposure prophylaxis in June 2025, which opens a market with fewer competing products but heavier public-health pricing pressure. Whether prevention revenue can offset eventual treatment-patent expiries in the early 2030s depends on uptake and on the price public payers will accept, and the first full year of launch data will say more about that than the approval itself.

02

Competitive advantage

Does the company have a moat? Yes, mostly inside HIV

Overall moat rating: Fairly Strong. Gilead has held roughly half the branded HIV market for five years and turns that position into cash at a rate few drugmakers match: $9.46 billion of free cash flow on $29.44 billion of 2025 revenue, a 28.9% net margin. The moat is real, and it is narrower than the company. HIV supplied 70.5% of revenue last year, and one tablet supplied nearly half of it. The pieces meant to become a second leg, chiefly cell therapy and Trodelvy, compete in fields where no single seller sets terms.

Two tests decide whether that adds up to a barrier or merely good execution. Concentration shows whether market structure keeps entrants out. Persistent excess returns show whether the incumbent's edge survives a full product cycle, which in pharmaceuticals means a decade or more. Gilead clears the first plainly and the second with qualifications.

Market position: dominant in HIV, ordinary elsewhere

Market position: Strong. Gilead reported $20.75 billion of HIV product sales in 2025 against $29.44 billion of total revenue. Biktarvy, the single-tablet regimen at the center of treatment, sold $14.33 billion, or 48.7% of the company. Aggregating product sales across the four branded sellers plus generic and regional manufacturers, Gilead holds roughly half the global HIV antiviral market, about twice ViiV Healthcare's share and several times Merck's.

No authority publishes a consistent global HIV share series. IQVIA tracks prescriptions in major markets but not on a uniform worldwide basis, Merck and Johnson & Johnson do not break out HIV revenue, and Gilead discloses by product rather than by market. The figures below are estimates built from company-reported antiviral sales, rounded, with the segment years restated to current presentation.

USD bn20212022202320242025
HIV product sales16.417.218.219.620.75
Biktarvy8.610.411.813.414.33
Total revenue27.3027.2827.1228.7529.44
HIV share of revenue60%63%67%68%70.5%

Stability of position: Fairly Strong. The share estimate has drifted up a few points since 2021, not down. HIV revenue rose every year, and Biktarvy's climb from $8.6 billion to $14.3 billion came partly at the expense of Gilead's own older regimens, which is the cheapest kind of share to win. A five-point swing over five years would suggest barriers are weak; a swing under two points would suggest they are strong. Gilead sits between those markers with the direction pointing the right way, which is uncommon in branded pharma.

One caveat keeps this from a higher rating. The HIV pool expanded over the period as treatment reached more patients and long-acting formats opened a new segment. In a growing market an incumbent can add revenue without winning a share fight. The test hardens when the pool stops growing, and that has not happened yet.

Profitability: high returns underneath noisy reporting

Profitability: Fairly Strong. Gilead earned $8.51 billion of net income in 2025. An estimate from reported operating income, tax and invested capital puts after-tax return on invested capital in the low twenties, comfortably above any plausible cost of capital for a company with this balance sheet.

The reported series is messier than that. Gilead expenses acquired in-process R&D immediately, so earnings swing with deal activity: the 2024 net margin was 1.7% after acquired R&D and impairments, and the first half of 2026 produced a net loss of $8.5 billion on $11.3 billion of acquired R&D, mainly Arcellx, Tubulis and Ouro. Equity fell from $22.7 billion at the end of 2025 to $11.7 billion at June 30, 2026. Adjust for those charges and returns have sat in the high teens to mid-20s for most of the decade. An average after-tax ROIC of 15% to 25% over ten years is the usual marker of a genuine advantage; Gilead clears the bottom of that band, though not by enough that the reported figures can be read year by year without adjustment.

USD bn20212022202320242025
Revenue27.3027.2827.1228.7529.44
Net income6.224.595.670.488.51
Net margin22.8%16.8%20.9%1.7%28.9%
Operating cash flow11.389.078.0110.8310.02
Free cash flow10.808.347.4210.309.46

A clean margin comparison with rivals is not possible: ViiV's economics sit inside GSK's consolidated reporting, and Merck's HIV line is too small to be broken out. What can be compared is scale and direction. Gilead's HIV sales are roughly twice ViiV's, and ViiV has been the seller losing relative ground in oral treatment even while its injectable franchise grew. Gilead's 79% gross margin in 2025 is ordinary for premium branded pharma. What distinguishes it is that the margin comes from a class where Gilead holds the standard of care, not from a diversified portfolio.

Overall: a strong franchise inside a merely good company

Overall rating: Fairly Strong. The market position rating is Strong and profitability is Fairly Strong, supported by five years of stable-to-rising share and returns well above the cost of capital. Three things keep it from Strong. Nearly half of revenue depends on one molecule. Payers, not Gilead, set the net price, and Medicare has begun to negotiate. And the legal protection carries an expiry date rather than an option to extend. The moat protects an annuity; it does not yet protect a growing one.

Where the advantage comes from and how long it can last

Three sources matter here: patient captivity, the scale economics of developing combination regimens, and a patent wall with dated gates. The first two reinforce each other. The third sets a deadline.

Customer captivity: Fairly Strong, and it carries the franchise

HIV is lifelong daily therapy, and the clinical goal is an undetectable viral load. That single fact does most of the work. A physician with a suppressed patient has little reason to change the regimen and a clear reason not to: a switch risks losing suppression, which is the outcome both patient and doctor care about. Prescribing is concentrated among a limited pool of infectious-disease specialists, and treatment guidelines name preferred regimens, several of which Gilead sells. A new patient is a contest; an existing, controlled patient usually is not.

The evidence shows up in the revenue line. HIV sales grew from $16.4 billion in 2021 to $20.75 billion in 2025, with Biktarvy still adding revenue in its eighth year on the market. Total revenue rose about 10% year over year in the second quarter of 2026, to $7.80 billion from $7.08 billion, despite a large acquired-R&D charge running through the income statement, and the cash-generating core kept funding both the dividend and the dealmaking.

Captivity has limits, and they are instructive. Payers stand between Gilead and the patient: three wholesalers, Cardinal Health, McKesson and Cencora, took about 74% of gross product sales in 2025, and rebates and discounts reduce what Gilead actually books well below list price. ViiV's long-acting injectable won business in the switch market, which shows that a better format can move a controlled patient. In prevention, where Gilead's lenacapavir was approved in June 2025, the buyer is often a public health program with a hard budget. The captivity is genuine and it is priced, not absolute.

Scale in development and manufacturing: Moderate

A modern HIV regimen is a combination, so the developer needs rights to several molecules, a large trial population and a regulatory package that beats the incumbent combination rather than matching it. Gilead spreads those fixed costs over a $20 billion franchise, which means a single successful program repays its development cost quickly and a failure is survivable. A smaller rival gets fewer bets. Manufacturing adds a second layer: long-acting formulations such as lenacapavir require nanosuspension production at commercial scale, a capability held by few contractors, and Gilead runs its own plants in Cork and Frederick.

The rating stops at Moderate because the advantage is measured against small biotech, not against Merck, GSK or Johnson & Johnson, all of which run comparable trial machinery and can license or acquire the same molecules. A 79% gross margin is not proof of scale economies when every branded pharma peer earns something similar. Scale here raises the odds of winning the next regimen. It does not stop a rival from entering the race.

Patents and settlements: Fairly Strong, with a date attached

Settlements signed in October 2025 bar US generic versions of Biktarvy until April 1, 2036, and lenacapavir's patents run to 2037. Add new-chemical-entity exclusivity and the clinical lead becomes a legal monopoly for a defined period. That is what allows the price and the margin.

The same regulatory system that blocks entry also sets price. Biktarvy appears on Medicare's negotiated-price list, and Gilead has said it expects the resulting price to be substantially lower. So the government is simultaneously the gatekeeper on entry and a counterparty on price, which is why the moat rates Fairly Strong and not Strong. The wall is also a deadline rather than a ramp: after 2036 the HIV franchise becomes a generic-priced business unless a successor regimen with its own patents has displaced it by then.

Durability: price is the nearer threat than generic entry

The obvious substitute is a better format. ViiV already sells a two-monthly injectable, and Gilead's own answer is twice-yearly lenacapavir, approved for prevention and used in treatment for heavily pretreated patients. If injectable prevention and treatment become the norm, the daily-tablet annuity narrows and the contest shifts to manufacturing and payer contracts, where Gilead's advantage is thinner. A functional cure or vaccine would end the annuity outright; the evidence does not yet establish a timeline, and near-term probability looks low.

Generic entry is dated and therefore manageable. The nearer risk is price. Medicare and Medicaid negotiations, plus public payers abroad, can cut revenue without touching a single prescription, and unlike a patent cliff that pressure arrives gradually enough to be absorbed without alarm. A 20% cut in the US net price would trim revenue by several billion dollars while volumes hold.

What would change this assessment is specific. HIV sales falling in a year with no patent expiry would falsify the captivity argument. Losing preferred-regimen status in a major guideline would do the same. A rival regimen beating Biktarvy in a head-to-head trial would mark the first real crack. None of that has happened.

The capital-allocation record bears on how much the moat is worth. Gilead expensed $11.3 billion of acquired in-process R&D in the first half of 2026, following $4.7 billion in 2024, and has not yet built a second franchise of comparable scale. A moat that protects a large annuity but cannot be reinvested at similar returns is worth less than its return on capital alone suggests. The HIV cash flows look secure through the early 2030s and legally protected to 2036 in the US; whether they compound after that depends on a successor regimen that does not yet exist.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Continue the comparison

Continue reading the full report

  1. Comparison and summaryHow Gilead Sciences Inc compares with its closest rivals, and our moat rating

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Gilead Sciences Inc